Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.40
+0.08 (+1.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $203.7M · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
21.6x
↑EV/EBITDA
13.1x
↑ROE
6.3%
↑Gross Margin
80.7%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.0%
FCF CAGR
-16.1%
FCF margin
17.7%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.15B · net income $278.6M · FCF $203.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.15B | $1.15B | $1.47B | $1.59B | $1.12B |
| Net Income | $278.6M | $278.6M | $375.6M | $327.9M | $190.8M |
| EBITDA | $357.2M | $357.2M | $470.3M | $367.5M | $257.9M |
| EPS | 0.27 | 0.27 | 0.36 | 0.31 | 0.18 |
| Gross Margin | 80.7% | 80.7% | 81.5% | 80.4% | 77.9% |
| Operating Margin | 23.6% | 23.6% | 25.0% | 20.7% | 18.3% |
| Net Margin | 24.2% | 24.2% | 25.5% | 20.6% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | — | — |
| Current Ratio | 11.09 | 11.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $203.7M | $203.7M | $138.4M | $353.6M | $344.8M |
| Returns | |||||
| ROE | 6.3% | 6.3% | 9.2% | 8.1% | 5.1% |
| Valuation | |||||
| P/E | 21.60 | 21.60 | 16.68 | 20.70 | 44.13 |
| EV/EBITDA | 13.08 | 13.08 | 12.07 | 16.83 | 29.96 |
| P/B | 1.28 | 1.28 | 1.53 | 1.68 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | -21.8% | -21.8% | -7.6% | 42.5% | — |
| EPS Growth | -25.8% | -25.8% | 14.5% | 71.9% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.6%
EPS terminal req.
$0.48
Spread vs growth
-47.5%
5Y implied EPS CAGR
16.8%
EPS terminal req.
$0.58
Spread vs growth
-42.7%
10Y implied EPS CAGR
13.4%
EPS terminal req.
$0.93
Spread vs growth
-39.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.2%
Start / end P/E
16.8x → 20.3x
EPS bridge
0.36 → 0.27
Residual
-5.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.